Coloplast profit falls 26% on tax hit despite 7% organic sales growth

Coloplast A/S reported a 26% decline in net profit to DKK 2.76 billion for the first nine months of its fiscal year, primarily due to extraordinary tax expenses tied to its Kerecis unit. Despite this, the medical device company demonstrated robust operational performance with 7% organic revenue growth to DKK 20.91 billion and a stable 27% EBIT margin. Coloplast maintained its full-year outlook for approximately 7% organic revenue growth and a 27-28% EBIT margin, signaling underlying business strength despite the one-off tax impact from the Kerecis intellectual property transfer.

Analysis

Coloplast A/S reported a 26% decline in nine-month net profit to DKK 2.76 billion, a figure heavily distorted by a one-off extraordinary tax expense related to the intellectual property transfer of its Kerecis unit. The underlying operational performance remains robust, evidenced by 7% organic revenue growth which strips out a 2% negative currency impact and a 1% effect from a divestment. Profitability at the operating level is steady, with EBIT increasing 4% to DKK 5.72 billion, maintaining a stable EBIT margin of 27%. Segment performance highlights strong momentum in Continence Care (+8%) and Voice and Respiratory Care (+9%). While the Advanced Wound Care segment reported an 8% decline, this was due to a specific DKK 20 million product return in China; critically, the high-growth Kerecis component within this segment expanded by 17%. The company faces regional headwinds, with Q3 sales falling 7% in emerging markets, including low growth in China. Despite these challenges and the significant tax impact, Coloplast has confidently reaffirmed its full-year guidance for approximately 7% organic revenue growth and an EBIT margin of 27-28%, signaling that the core business trajectory is intact.

Key Decisions for Investors

• Investors should look past the headline net profit decline, as it is driven by a non-recurring tax event, and focus instead on the strong 7% organic growth and stable EBIT margins as key indicators of underlying business health.
• Monitor the performance of high-growth drivers, particularly the Kerecis unit which grew 17%, while scrutinizing the persistent weakness in emerging markets and China as a primary risk factor for future growth.
• The reaffirmed full-year guidance provides a solid anchor for valuation, but portfolios should account for the elevated near-term effective tax rate of approximately 40% and a net debt level of 2.6 times EBITDA when assessing the company's financial profile.